Brief: Theranexus Announces First European Authorization For Clinical Study Of Phase 2 With Thn 102 In Parkinson's Disease
19/04/2018 17:11
April 19 (Reuters) - THERANEXUS SA ALTHX.PA :
* ANNOUNCES FIRST EUROPEAN AUTHORIZATION FOR CLINICAL STUDY
OF
PHASE 2 WITH THN 102 IN PARKINSON'S DISEASE
* FIRST GREEN LIGHT FOR LAUNCH OF MULTICENTRIC INTERNATIONAL
STUDY
PHASE 2
Source text : https://bit.ly/2EXTIJP
Further company coverage: ALTHX.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease